Trials / Completed
CompletedNCT03456726
Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation
A Phase 2 Study of Tazemetostat in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label, Phase 2 study to assess the efficacy and safety of tazemetostat in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) with EZH2 gene mutation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tazemetostat | Tazemetostat will be provided as a 200 mg oral tablet. |
Timeline
- Start date
- 2018-04-09
- Primary completion
- 2021-12-17
- Completion
- 2021-12-17
- First posted
- 2018-03-07
- Last updated
- 2022-12-16
- Results posted
- 2022-12-16
Locations
28 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03456726. Inclusion in this directory is not an endorsement.